II. Indications
-
HIV Infection (combination therapy)
- Was the most commonly used NNRTI in 2011 and available in combination (Atripla)
- NNRTIs carry a high risk of induced HIV resistance
- Never use NNRTIs as monotherapy in HIV Infection
III. Contraindications
- Moderate to severe liver disease (Child-Pugh B or C)
- Age 3 months to 3 years due to variable CYP2B6 metabolism
IV. Mechanism
- See Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- First generation NNRTI
V. Dosing
- Take on an empty Stomach
- May sprinkle capsule contents on 1-2 teaspoons of food
- Avoid food for 2 hours after dose
- Adult (or child weight >40 kg)
- Efavirenz 600 mg orally on an empty Stomach at bedtime
- Child (age >3 months and weight >3.5 kg)
- Avoid Efavirenz in age 3 months to 3 years due to variable CYP2B6 metabolism
- Weight 3.5 to 5 kg: Give 100 mg orally at bedtime
- Weight 5.0 to 7.5 kg: Give 150 mg orally at bedtime
- Weight 7.5 to 15 kg: Give 200 mg orally at bedtime
- Weight 15 to 20 kg: Give 250 mg orally at bedtime
- Weight 20 to 25 kg: Give 300 mg orally at bedtime
- Weight 25 to 33 kg: Give 350 mg orally at bedtime
- Weight 33 to 40 kg: Give 400 mg orally at bedtime
- Weight >40 kg: Give 600 mg orally at bedtime
VI. Adverse Effects: Neurologic
- Timing
- Take Efavirenz at bedtime
- Onset 1 to 3 hours after dose
- Symptoms abate after 1 to 2 weeks
- Affect 50% at 1 month
- Affect 23% at 3 months
- Patients typically return to baseline at 6 months
- Symptoms
- Dizziness
- Headache
- Insomnia
- Difficulty concentrating
- Vivid dreams
- Nightmares
- Hallucinations
- Suicidality
VII. Adverse Effects: Miscellaneous
- Rash
- Consider Antihistamine coadministration with dose
- Stop Efavirenz for severe rash
-
Hyperlipidemia
- Risk of increased Serum Triglycerides and LDL Cholesterol
-
QTc Prolongation
- Avoid with known QTc Prolongation or other medications that cause Drug-Induced QTc Prolongation
- Hepatotoxicity
- Contraindicated in moderate to severe liver disease (Child-Pugh B or C)
- Obtain baseline LFTs and periodically
- Consider stopping Efavirenz if serum transaminase increased >5 fold over baseline
VIII. Safety
- Avoid in Lactation
- Pregnancy
- Potentially Teratogenic (risk of Neural Tube Defects)
- Package labeling recommends against use in pregnancy, but HIV Perinatal guidelines use in all trimesters
- Pregnancy registry exists
IX. Drug Interactions
- Take on empty Stomache at bedtime
- Metabolized by CYP2B6
- Avoid in age 3 months to 3 years due to variable CYP2B6 metabolism (risk of both low efficacy and toxicity)
- Induces CYP3A4 and CYP2B6
- Many significant Drug Interactions (use formal Drug Interaction application to review)
-
Voriconazole
- Decrease Efavirenz dose to 300 mg orally once daily
- Maintain Voriconazole at 400 mg orally twice daily
- Decreases serum levels of some Protease Inhibitors
- Avoid concurrent use of Saquinavir
- Raise dose of Indinavir to 1000 mg PO q8h
-
Clarithromycin
- Clarithromycin increases risk of Efavirenz associated rash
- Efavirenz decreases Clarithromycin level
- Azithromycin not effected
- Contraceptives
- Efavirenz decreases efficacy of combined Oral Contraceptives, Progestin Only Pill and Etonogestrel Drug Implant
-
Drug-Induced QTc Prolongation
- Avoid with other agents that prolong QTc
- Urine Drug Screen
X. Resources
Images: Related links to external sites (from Bing)
Related Studies
efavirenz (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
EFAVIRENZ 600 MG TABLET | Generic | $3.08 each |
EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB | Generic | $4.50 each |